Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer.

The Journal of clinical investigation - 4 Feb 2025

Yu Fang, Zheng Shikan, Yu Chunjie, Gao Sanhui, Shen Zuqi, Nar Rukiye, Liu Zhexin, Huang Shuang, Wu Lizi, Gu Tongjun, Qian Zhijian

Abstract excerpt

Constitutively active mutations of KRAS are prevalent in non-small cell lung cancer (NSCLC). However, the relationship between these mutations and resistance to platinum-based chemotherapy and the underlying mechanisms remain elusive. In this study, we demonstrate that KRAS mutants confer resistance to platinum in NSCLC. Mechanistically, KRAS mutants mediate platinum resistance in NSCLC cells by activating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mice, Nude

Share to Neoplasm Proteins

Share to Protein Processing, Post-Translational

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA, Neoplasm

Source

Open in PubMed Open full text

Identifiers

PMID: 39960727
DOI: 10.1172/JCI185149
PMCID: PMC11910214

Genes

KRAS
ALKBH5
DDB2
METTL3
XPC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer.PMID 39960727Read ↗

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage.Semantic proximity Read ↗

m⁶A Demethylase ALKBH5 Promotes Tumor Cell Proliferation by Destabilizing IGF2BPs Target Genes and Worsens the Prognosis of Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

m <sup>6</sup> A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small cell lung cancerSemantic proximity Read ↗

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.Semantic proximity Read ↗

Suppressing the OTUD7A/KDM5B/GABPA axis enhances the sensitivity of cisplatin through inducing ferroptosis in KRAS-mutant LUAD.Semantic proximity Read ↗

M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLCSemantic proximity Read ↗

Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations.Semantic proximity Read ↗

Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cellsSemantic proximity Read ↗

LKB1 Loss Upregulates ALKBH5 and Contributes to Aggressive Phenotypes of KRAS Mutated Lung CancerSemantic proximity Read ↗

The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung CancerSemantic proximity Read ↗

Mutant <i>KRAS</i> dosage contributes to heterogeneity in lung cancer therapeutic responseSemantic proximity Read ↗

Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.